ABBV vs ACAD: fair value comparison
AbbVie Inc. and Acadia Pharmaceuticals Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ACAD currently sits closer to the top of our ranking by discount to fair value. ACAD carries the stronger quality grade.
| ABBV | ACAD | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $276.47 | $19.12 |
| 12-month range | $197.38–$285.42 | $18.62–$30.57 |
| Rank by discount to fair value | #78 of 108 Healthcare | #74 of 108 Healthcare |
| Quality grade | B | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Overbought | Oversold |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: ABBV fair value analysis · ACAD fair value analysis